questionsmedicales.fr
États, signes et symptômes pathologiques
Processus pathologiques
Fibrose
Fibrose : Questions médicales fréquentes
Termes MeSH sélectionnés :
Disruptive, Impulse Control, and Conduct Disorders
Diagnostic
5
Fibrose pulmonaire
Biopsie
Imagerie médicale
Tests sanguins
Inflammation
Fonction hépatique
Échographie
Fibrose hépatique
Imagerie
Radiologie
Fibrose
Opacités
Pneumonie
Cirrhose
Diagnostic différentiel
Symptômes
5
Fibrose pulmonaire
Toux
Essoufflement
Fibrose hépatique
Douleur abdominale
Symptômes
Fibrose cardiaque
Palpitations
Œdèmes
Perte de poids
Fibrose
Malabsorption
Fibrose systémique
Douleurs articulaires
Raideur cutanée
Prévention
5
Prévention
Tabagisme
Polluants
Fibrose hépatique
Mode de vie sain
Vaccination
Examens réguliers
Détection précoce
Fibrose
Alimentation
Antioxydants
Prévention
Maladies chroniques
Diabète
Hypertension
Traitements
5
Fibrose pulmonaire
Antifibrotiques
Réhabilitation pulmonaire
Transplantation
Chirurgie
Fibrose
Fibrose hépatique
Antiviraux
Médicaments
Physiothérapie
Fibrose
Qualité de vie
Traitements naturels
Antioxydants
Consultation médicale
Complications
5
Complications
Insuffisance respiratoire
Infections pulmonaires
Cirrhose
Fibrose hépatique
Complications
Fibrose cardiaque
Insuffisance cardiaque
Accidents vasculaires cérébraux
Qualité de vie
Fibrose
Limitations
Complications psychologiques
Anxiété
Dépression
Facteurs de risque
5
Facteurs de risque
Tabagisme
Infections
Âge
Fibrose
Facteurs de risque
Maladies auto-immunes
Sclérodermie
Fibrose
Diabète
Fibrose hépatique
Stéatose
Exposition professionnelle
Fibrose
Produits chimiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fibrose : Questions médicales les plus fréquentes",
"headline": "Fibrose : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fibrose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-06",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fibrose"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Processus pathologiques",
"url": "https://questionsmedicales.fr/mesh/D010335",
"about": {
"@type": "MedicalCondition",
"name": "Processus pathologiques",
"code": {
"@type": "MedicalCode",
"code": "D010335",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cicatrice hypertrophique",
"alternateName": "Cicatrix, Hypertrophic",
"url": "https://questionsmedicales.fr/mesh/D017439",
"about": {
"@type": "MedicalCondition",
"name": "Cicatrice hypertrophique",
"code": {
"@type": "MedicalCode",
"code": "D017439",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.274.505"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chéloïde",
"alternateName": "Keloid",
"url": "https://questionsmedicales.fr/mesh/D007627",
"about": {
"@type": "MedicalCondition",
"name": "Chéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007627",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.274.510"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Adhérences tissulaires",
"alternateName": "Tissue Adhesions",
"url": "https://questionsmedicales.fr/mesh/D000267",
"about": {
"@type": "MedicalCondition",
"name": "Adhérences tissulaires",
"code": {
"@type": "MedicalCode",
"code": "D000267",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.274.840"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cirrhose du foie",
"alternateName": "Liver Cirrhosis",
"url": "https://questionsmedicales.fr/mesh/D008103",
"about": {
"@type": "MedicalCondition",
"name": "Cirrhose du foie",
"code": {
"@type": "MedicalCode",
"code": "D008103",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.412"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cirrhose biliaire",
"alternateName": "Liver Cirrhosis, Biliary",
"url": "https://questionsmedicales.fr/mesh/D008105",
"about": {
"@type": "MedicalCondition",
"name": "Cirrhose biliaire",
"code": {
"@type": "MedicalCode",
"code": "D008105",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.412.400"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Fibrose systémique néphrogénique",
"alternateName": "Nephrogenic Fibrosing Dermopathy",
"url": "https://questionsmedicales.fr/mesh/D054989",
"about": {
"@type": "MedicalCondition",
"name": "Fibrose systémique néphrogénique",
"code": {
"@type": "MedicalCode",
"code": "D054989",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fibrose péritonéale",
"alternateName": "Peritoneal Fibrosis",
"url": "https://questionsmedicales.fr/mesh/D056627",
"about": {
"@type": "MedicalCondition",
"name": "Fibrose péritonéale",
"code": {
"@type": "MedicalCode",
"code": "D056627",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fibrose pulmonaire",
"alternateName": "Pulmonary Fibrosis",
"url": "https://questionsmedicales.fr/mesh/D011658",
"about": {
"@type": "MedicalCondition",
"name": "Fibrose pulmonaire",
"code": {
"@type": "MedicalCode",
"code": "D011658",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.644"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fibrose rétropéritonéale",
"alternateName": "Retroperitoneal Fibrosis",
"url": "https://questionsmedicales.fr/mesh/D012185",
"about": {
"@type": "MedicalCondition",
"name": "Fibrose rétropéritonéale",
"code": {
"@type": "MedicalCode",
"code": "D012185",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.355.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Fibrose",
"alternateName": "Fibrosis",
"code": {
"@type": "MedicalCode",
"code": "D005355",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nikolaos G Frangogiannis",
"url": "https://questionsmedicales.fr/author/Nikolaos%20G%20Frangogiannis",
"affiliation": {
"@type": "Organization",
"name": "The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: nikolaos.frangogiannis@einsteinmed.org."
}
},
{
"@type": "Person",
"name": "Pierre-Régis Burgel",
"url": "https://questionsmedicales.fr/author/Pierre-R%C3%A9gis%20Burgel",
"affiliation": {
"@type": "Organization",
"name": "Université Paris Cité and Institut Cochin, Inserm U1016, Paris, France."
}
},
{
"@type": "Person",
"name": "Jane C Davies",
"url": "https://questionsmedicales.fr/author/Jane%20C%20Davies",
"affiliation": {
"@type": "Organization",
"name": "National Heart & Lung Institute, Imperial College London, London, UK."
}
},
{
"@type": "Person",
"name": "Na Liu",
"url": "https://questionsmedicales.fr/author/Na%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China."
}
},
{
"@type": "Person",
"name": "Ruoshui Li",
"url": "https://questionsmedicales.fr/author/Ruoshui%20Li",
"affiliation": {
"@type": "Organization",
"name": "The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct.",
"datePublished": "2022-12-01",
"url": "https://questionsmedicales.fr/article/36370093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/add.16086"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic prediction of impulse control disorders in Parkinson's disease.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35762106",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acn3.51569"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma.",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36149404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/WNN.0000000000000320"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36125673",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11154-022-09753-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "APOE contributes to longitudinal impulse control disorders progression in Parkinson's disease.",
"datePublished": "2024-09-27",
"url": "https://questionsmedicales.fr/article/39334114",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12888-024-06084-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Fibrose",
"item": "https://questionsmedicales.fr/mesh/D005355"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fibrose - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fibrose",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fibrose",
"description": "Comment diagnostique-t-on la fibrose pulmonaire ?\nQuels tests sanguins sont utiles pour la fibrose ?\nLa fibrose peut-elle être détectée par échographie ?\nQuels sont les signes radiologiques de la fibrose ?\nLa fibrose peut-elle être confondue avec d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fibrose",
"description": "Quels sont les symptômes de la fibrose pulmonaire ?\nLa fibrose hépatique provoque-t-elle des douleurs ?\nQuels signes indiquent une fibrose cardiaque ?\nLa fibrose peut-elle entraîner une perte de poids ?\nQuels symptômes sont associés à la fibrose systémique ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fibrose",
"description": "Comment prévenir la fibrose pulmonaire ?\nPeut-on prévenir la fibrose hépatique ?\nLes examens réguliers aident-ils à prévenir la fibrose ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe contrôle des maladies chroniques aide-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fibrose",
"description": "Quels traitements existent pour la fibrose pulmonaire ?\nLa chirurgie est-elle une option pour la fibrose ?\nQuels médicaments sont utilisés pour la fibrose hépatique ?\nLa physiothérapie aide-t-elle en cas de fibrose ?\nY a-t-il des traitements naturels pour la fibrose ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fibrose",
"description": "Quelles sont les complications de la fibrose pulmonaire ?\nLa fibrose hépatique peut-elle entraîner une cirrhose ?\nQuels risques sont associés à la fibrose cardiaque ?\nLa fibrose peut-elle affecter la qualité de vie ?\nY a-t-il des complications psychologiques liées à la fibrose ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fibrose",
"description": "Quels sont les facteurs de risque de la fibrose pulmonaire ?\nL'âge est-il un facteur de risque pour la fibrose ?\nLes maladies auto-immunes augmentent-elles le risque de fibrose ?\nLe diabète est-il un facteur de risque pour la fibrose hépatique ?\nL'exposition professionnelle influence-t-elle le risque de fibrose ?",
"url": "https://questionsmedicales.fr/mesh/D005355?mesh_terms=Disruptive,+Impulse+Control,+and+Conduct+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la fibrose pulmonaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens d'imagerie, des tests fonctionnels pulmonaires et parfois une biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour la fibrose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour évaluer les marqueurs inflammatoires et la fonction hépatique peuvent être effectués."
}
},
{
"@type": "Question",
"name": "La fibrose peut-elle être détectée par échographie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie peut aider à visualiser la fibrose dans certains organes comme le foie."
}
},
{
"@type": "Question",
"name": "Quels sont les signes radiologiques de la fibrose ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des opacités, des réticulations et des anomalies de la structure tissulaire."
}
},
{
"@type": "Question",
"name": "La fibrose peut-elle être confondue avec d'autres maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec des maladies comme la pneumonie ou la cirrhose."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la fibrose pulmonaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une toux persistante, un essoufflement et une fatigue chronique."
}
},
{
"@type": "Question",
"name": "La fibrose hépatique provoque-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut causer des douleurs abdominales et une sensation de lourdeur dans l'abdomen."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une fibrose cardiaque ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des palpitations, un essoufflement à l'effort et des œdèmes."
}
},
{
"@type": "Question",
"name": "La fibrose peut-elle entraîner une perte de poids ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fibrose peut causer une perte de poids due à une mauvaise absorption des nutriments."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à la fibrose systémique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, une raideur cutanée et des troubles circulatoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir la fibrose pulmonaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme, réduire l'exposition à des polluants et traiter les infections respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la fibrose hépatique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en adoptant un mode de vie sain, en évitant l'alcool et en se vaccinant contre l'hépatite."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir la fibrose ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent détecter précocement des maladies pouvant mener à la fibrose."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée riche en antioxydants peut aider à prévenir la fibrose."
}
},
{
"@type": "Question",
"name": "Le contrôle des maladies chroniques aide-t-il ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien gérer des maladies comme le diabète ou l'hypertension peut réduire le risque de fibrose."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la fibrose pulmonaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments antifibrotiques, la réhabilitation pulmonaire et l'oxygénothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option pour la fibrose ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas avancés, une transplantation d'organe peut être envisagée."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour la fibrose hépatique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments pour traiter la cause sous-jacente, comme les antiviraux pour l'hépatite, sont utilisés."
}
},
{
"@type": "Question",
"name": "La physiothérapie aide-t-elle en cas de fibrose ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut améliorer la fonction pulmonaire et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour la fibrose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines approches comme les antioxydants peuvent aider, mais il faut consulter un médecin."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la fibrose pulmonaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance respiratoire, les infections pulmonaires et les embolies."
}
},
{
"@type": "Question",
"name": "La fibrose hépatique peut-elle entraîner une cirrhose ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fibrose hépatique peut évoluer vers une cirrhose, entraînant des complications graves."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à la fibrose cardiaque ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent l'insuffisance cardiaque, les arythmies et les accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "La fibrose peut-elle affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la qualité de vie en limitant les activités quotidiennes et en causant de la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications psychologiques liées à la fibrose ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent éprouver de l'anxiété et de la dépression en raison de leur état de santé."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de la fibrose pulmonaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition à des substances toxiques et des infections antérieures."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour la fibrose ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de fibrose augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles le risque de fibrose ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme la sclérodermie peuvent prédisposer à la fibrose dans divers organes."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque pour la fibrose hépatique ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque de fibrose hépatique en raison de la stéatose."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle influence-t-elle le risque de fibrose ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des professions exposant à des poussières ou des produits chimiques peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 02/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: nikolaos.frangogiannis@einsteinmed.org.
Publications dans "Fibrose" :
2 publications dans cette catégorie
Affiliations :
Université Paris Cité and Institut Cochin, Inserm U1016, Paris, France.
Department of Respiratory Medicine and National Reference Center for Cystic Fibrosis, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.
Publications dans "Fibrose" :
2 publications dans cette catégorie
Affiliations :
National Heart & Lung Institute, Imperial College London, London, UK.
St Thomas' NHS Trust, London, UK.
Royal Brompton Hospital, Part of Guy's & St Thomas' Trust, London, UK.
Publications dans "Fibrose" :
2 publications dans cette catégorie
Affiliations :
Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China.
Publications dans "Fibrose" :
2 publications dans cette catégorie
Affiliations :
The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, United States of America.
Publications dans "Fibrose" :
2 publications dans cette catégorie
Affiliations :
1Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Adult Cystic Fibrosis Centre, Royal Brompton Hospital and Imperial College, London SW3 6NP, United Kingdom. Electronic address: n.simmonds@imperial.ac.uk.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA. rgzhao@buffalo.edu.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Section of Pulmonary and Critical Care, Department at University of Chicago, 5841 South Maryland Avenue, MC 6076, Chicago, IL 60637, USA.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Interstitial Lung Disease Program, Section of Pulmonary/Critical Care, University of Chicago, Chicago, IL, USA. Electronic address: deji@uchicago.edu.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University Hospital of Padova, Padua, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Medical and Surgical Sciences, University Hospital of Modena, Respiratory Diseases Unit and Centre for Rare Lung Diseases, University of Modena Reggio Emilia, Modena, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Medical and Surgical Sciences, University Hospital of Modena, Internal Medicine Unit, University of Modena Reggio Emilia, Modena, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Medical and Surgical Sciences, University Hospital of Modena, Respiratory Diseases Unit and Centre for Rare Lung Diseases, University of Modena Reggio Emilia, Modena, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Medical and Surgical Sciences, University Hospital of Modena, Respiratory Diseases Unit and Centre for Rare Lung Diseases, University of Modena Reggio Emilia, Modena, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Surgical, Oncological and Gastroenterological Sciences, Unit of Gastroenterology, University of Padova, Padua, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Surgical, Oncological and Gastroenterological Sciences, Unit of Gastroenterology, University of Padova, Padua, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Medical and Surgical Sciences, University Hospital of Modena, Internal Medicine Unit, University of Modena Reggio Emilia, Modena, Italy.
Publications dans "Fibrose" :
1 publication dans cette catégorie
Affiliations :
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University Hospital of Padova, Padua, Italy.
Publications dans "Fibrose" :
Impulse control disorders (ICDs) are iatrogenic and idiopathic conditions with psychosocial and economic consequences for the affected individuals and their families (e.g. bankruptcy and divorce). How...
To contextualize the ICD diagnostic construct, we provided an overview of its origins in past centuries and followed its development across multiple editions of the Diagnostic and Statistical Manual a...
Two independent roots of the ICD construct emerged: (a) the interest in behavioral excess as expressed in encyclopedic compilations (18th century) and (b) the juridical debate on disruptive conduct an...
The reasons that made impulse control disorders (ICDs) difficult to define from their first conceptualization are the same reasons that now complicate taxonomic efforts and diagnosis. Tracing back ICD...
To develop a clinico-genetic predictor of impulse control disorder (ICD) risk in Parkinson's disease (PD)....
In 5770 individuals from three PD cohorts (the 23andMe, Inc.; the University of Pennsylvania [UPenn]; and the Parkinson's Progression Markers Initiative [PPMI]), we used a discovery-replication strate...
By GWAS, we discovered four new loci associated with ICD at p-values of 4.9e-07 to 1.3e-06...
In this multi-cohort, international study, we developed an easily computed clinico-genetic tool, the ICD-RS, that substantially enriches for subgroups of PD at very high versus very low risk for ICD, ...
Studies have reported an increase in the incidence of impulse control disorders (ICDs) in patient groups treated with dopamine agonists (DAAs), especially in Parkinson disease (PD). However, very few ...
To see whether a DAA by itself causes ICDs in individuals with a prolactinoma by controlling the susceptibility to impulsivity by excluding individuals with other risk factors for ICDs....
We compared the performance of 31 individuals with a prolactinoma receiving DAA therapy (DAA+) on various behavioral scales and the Iowa gambling task (IGT), a neuropsychological instrument that measu...
There was no significant difference among the groups concerning performance on the Zuckerman Sensation Seeking Scale-V, Minnesota Impulse Disorders Interview, Barratt Impulsiveness Scale-11, or IGT. N...
Individuals who are under treatment with low-dose, D 2 -selective DAAs for a prolactinoma do not face an increased risk for ICDs, especially when they are carefully screened for any psychiatric comorb...
Dopamine agonists (DAs) represent a mainstay of therapy for hyperprolactinemia and prolactinomas. The widespread use of DAs, including bromocriptine, cabergoline and (in some countries) quinagolide, h...
Impulse control disorders (ICDs) are an increasingly recognized complication in Parkinson disease (PD). The pathogenesis of ICDs is currently unclear. Few genetic studies have been conducted in this a...
We aimed to ascertain the correlation between APOE and ICDs, and identify clinical predictors of ICDs in PD....
This study included 287 PD patients from the Parkinson's Progression Markers Initiative. They were followed up to investigate the progression of ICDs over a period of 5 years. The cumulative incidence...
44.3% (31/70) patients with APOE ɛ4 and 32.3% (70/217) patients without APOE ɛ4 developed ICDs during the five-year follow up period. There were significant differences between the PD with and without...
This study provides important insights into the potential role of the APOE gene in the development of ICDs in PD. Further studies are needed to confirm our findings and to investigate the underlying m...
This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disord...
The longitudinal cohort consisted of consecutive nondemented PD patients with no ICD history. We recorded FRN signals while they performed a gambling task. We calculated the mean amplitude difference ...
Between October 7, 2015 and December 16, 2016, we screened 120 patients. Among them, 94 patients performed the gambling and 92 completed the follow-up. Eighteen patients developed ICDs during follow-u...
Reward-processing differences measured by FRN signals precede ICD development in PD. This neurophysiological marker permits identification of patients with high risk of ICD development. ANN NEUROL 202...
Impulse control disorders (ICDs) in Parkinson's disease (PD) are increasingly recognized as clinically significant non-motor features that potentially impair the quality of life. White matter hyperint...
Some patients with Parkinson's disease (PD) experience impulse control disorders (ICDs), characterized by deficient voluntary control over impulses, drives, or temptations regarding excessive hedonic ...
Impulse control disorders (e.g. pathological gambling, hypersexuality) may develop as adverse reactions to drugs. Pathogenetic hypotheses have mainly focused on D3-receptor agonism, and switching to a...
We aimed to identify targets potentially contributing to pathologic impulsivity....
We performed a pharmacovigilance-pharmacodynamic study on dopamine agonists and antipsychotics using the Food and Drug Administration Adverse Event Reporting System (January 2004-December 2021). We es...
Among 19 887 reports of impulsivity, 5898 recorded an antipsychotic, and 3100 a dopamine agonist. The more robust signals concerned aripiprazole (N = 3091; median information component [95% confidence...
Our results supported the role of D3-receptor agonism in inducing impulsivity in dopamine receptor agonists and identified a potential role of 5-HT1a receptor agonism in antipsychotics. Investigating ...
The impact of non-motor symptoms is often overlooked in favour of the motor symptoms when managing Parkinson's disease resulting in suboptimal patient outcomes. This study aimed to characterise the no...